FILED PURSUANT TO RULE 424(b)(3) AND (c)
FILE NUMBER 333-61413
SEVENTEENTH PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED AUGUST 24, 1998
4,185,124 SHARES
LYCOS, INC.
COMMON STOCK
This Seventeenth Prospectus Supplement (the "Seventeenth Prospectus Supplement")
supplements the Prospectus dated August 24, 1998 (the "Prospectus"), the
Prospectus Supplement dated September 15, 1998 (the "First Prospectus
Supplement"), the Second Prospectus Supplement dated October 28, 1998 (the
"Second Prospectus Supplement"), the Third Prospectus Supplement dated November
12, 1998 (the "Third Prospectus Supplement"), the Fourth Prospectus Supplement
dated November 18, 1998 (the "Fourth Prospectus Supplement"), the Fifth
Prospectus Supplement dated November 19, 1998 (the "Fifth Prospectus
Supplement"), the Sixth Prospectus Supplement dated December 1, 1998 (the "Sixth
Prospectus Supplement"), the Seventh Prospectus Supplement dated December 2,
1998 (the "Seventh Prospectus Supplement"), the Eighth Prospectus Supplement
dated December 4, 1998 (the "Eighth Prospectus Supplement"), the Ninth
Supplement dated December 21, 1998 (the "Ninth Prospectus Supplement"), the
Tenth Prospectus Supplement dated December 28, 1998 (the "Tenth Prospectus
Supplement"), the Eleventh Prospectus Supplement dated January 14, 1999 (the
"Eleventh Prospectus"), the Twelfth Prospectus Supplement dated February 12,
1999 (the "Twelfth Prospectus Supplement"), the Thirteenth Prospectus Supplement
dated March 2, 1999 (the "Thirteenth Prospectus Supplement"), the Fourteenth
Prospectus Supplement dated March 25, 1999 (the "Fourteenth Prospectus
Supplement"), the Fifteenth Prospectus Supplement dated April 27, 1999 (the
"Fifteenth Prospectus") and the Sixteenth Prospectus Supplement dated June 16,
1999 of Lycos, Inc. ("Lycos" or the "Company") relating to the public offering,
which is not being underwritten, and sale of up to 4,185,124 shares of Common
Stock, par value $0.01 per share (the "Shares") of the Company, which may be
offered and sold from time to time by certain stockholders of the Company or by
pledgees, donees, transferees or other successors in interest that receive such
shares as a gift, partnership distribution or other non-sale related transfer
(the "Selling Stockholders"). The Company will receive no part of the proceeds
of such sales. The Shares were originally issued or reserved for issuance by the
Company in connection with the Company's acquisition of WhoWhere? Inc., a
California corporation, by and through a merger of a wholly-owned subsidiary of
Lycos, What Acquisition Corp., with and into WhoWhere? Inc. (the "Acquisition").
The "Selling Stockholders" Section of the Prospectus, the First Prospectus
Supplement, the Second Prospectus Supplement, the Third Prospectus Supplement,
the Fourth Prospectus Supplement, the Fifth Prospectus Supplement, the Sixth
Prospectus Supplement, the Seventh Prospectus Supplement, the Eighth Prospectus
Supplement, the Ninth Prospectus
<PAGE>
Supplement, the Tenth Prospectus Supplement, the Eleventh Prospectus Supplement,
the Twelfth Prospectus Supplement, the Thirteenth Prospectus Supplement, the
Fourteenth Prospectus Supplement, the Fifteenth Prospectus Supplement and the
Sixteenth Prospectus Supplement are hereby supplemented to reflect the gift made
by Audrey Maclean & Michael M. Clair TTEES FBO Audrey Maclean & Michael Clair
Trust DTD 12/1/90 to (i) Markkula Center for Applied Ethics in the amount of 105
shares; (ii) Josephine Clair in the amount of 105 shares; (iii) Stanford
University Dept. of Athletics Volleyball in the amount of 520 shares; (iv)
Hospice of the Valley in the amount of 55 shares; (v) V Foundation for Cancer
Research in the amount of 125 shares; and (vi) Audrey Maclean Sr. in the amount
of 210 shares after the date of the Prospectus, the First Prospectus Supplement,
the Second Prospectus Supplement, the Third Prospectus Supplement, the Fourth
Prospectus Supplement, the Fifth Prospectus Supplement, the Sixth Prospectus
Supplement, the Seventh Prospectus Supplement, the Eighth Prospectus Supplement,
the Ninth Prospectus Supplement, the Tenth Prospectus Supplement, the Eleventh
Prospectus Supplement, the Twelfth Prospectus Supplement, the Thirteenth
Prospectus Supplement, the Fourteenth Prospectus Supplement, the Fifteenth
Prospectus Supplement and the Sixteenth Prospectus Supplement. This Seventeenth
Prospectus Supplement should be read in conjunction with the Prospectus, the
First Prospectus Supplement, the Second Prospectus Supplement, the Third
Prospectus Supplement, the Fourth Prospectus Supplement, the Fifth Prospectus
Supplement, the Sixth Prospectus Supplement, the Seventh Prospectus Supplement,
the Eighth Prospectus Supplement, the Ninth Prospectus Supplement, the Tenth
Prospectus Supplement, the Eleventh Prospectus Supplement, the Twelfth
Prospectus Supplement, the Thirteenth Prospectus Supplement, the Fourteenth
Prospectus Supplement, the Fifteenth Prospectus Supplement and the Sixteenth
Prospectus Supplement, and is qualified by reference to the Prospectus, the
First Prospectus Supplement, the Second Prospectus Supplement, the Third
Prospectus Supplement, the Fourth Prospectus Supplement, the Fifth Prospectus
Supplement, the Sixth Prospectus Supplement, the Seventh Prospectus Supplement,
the Eighth Prospectus Supplement, the Ninth Prospectus Supplement, the Tenth
Prospectus Supplement, the Eleventh Prospectus Supplement, the Twelfth
Prospectus Supplement, the Thirteenth Prospectus Supplement, the Fourteenth
Prospectus Supplement, the Fifteenth Prospectus Supplement and the Sixteenth
Prospectus Supplement, except to the extent that the information herein
contained supersedes the information contained in the Prospectus, the First
Prospectus Supplement, the Second Prospectus Supplement, the Third Prospectus
Supplement, the Fourth Prospectus Supplement, the Fifth Prospectus Supplement,
the Sixth Prospectus Supplement, the Seventh Prospectus Supplement, the Eighth
Prospectus Supplement, the Ninth Prospectus Supplement, the Tenth Prospectus
Supplement, the Eleventh Prospectus Supplement, the Twelfth Prospectus, the
Thirteenth Prospectus Supplement, the Fourteenth Prospectus Supplement, the
Fifteenth Prospectus Supplement and the Sixteenth Prospectus Supplement.
Capitalized terms used in this Seventeenth Prospectus Supplement and not
otherwise defined herein have the meanings specified in the Prospectus.
<PAGE>
THE DATE OF THIS SIXTEENTH PROSPECTUS SUPPLEMENT IS JULY 6, 1999
SELLING STOCKHOLDERS
On July 2, 1999, an aggregate of one thousand one hundred twenty
(1,120) of the Shares beneficially owned by Audrey Maclean & Michael M. Clair
TTEES FBO Audrey Maclean & Michael Clair Trust DTD 12/1/90 reflected in the
Prospectus and the supplements thereto were gifted to (i) Markkula Center for
Applied Ethics in the amount of 105 shares; (ii) Josephine Clair in the amount
of 105 shares; (iii) Stanford University Dept. of Athletics Volleyball in the
amount of 520 shares; (iv) Hospice of the Valley in the amount of 55 shares; (v)
V Foundation for Cancer Research in the amount of 125 shares' and (vi) Audrey
Maclean Sr. in the amount of 210 shares . The table of Selling Stockholders in
the Prospectus and the supplements thereto are hereby amended to reflect such
gift and supplemented to specifically include Shares received in such gift.
